Key Investor Signals
Reached nearly 30,000 paying subscribers within a year of launch
Belle reported close to 30,000 paying users for its international app by June 2025, less than a year after launching on iOS and Android.
Two randomized controlled trials with three universities
Belle's eight-week cognitive behavioral therapy program has been evaluated through two . The first involved and ; the second and larger German study involves .
CE-marked Class I app pursuing German insurer reimbursement
Belle reports status and has held discussions with German about coverage. provides an entry requirement for the pathway, while the support the evidence needed for insurer adoption.
Other Positive Signals
- Made the Belle Ring available to order for $299, with a free sizing kit shipped before the ring.
- Holds a 4.8 out of 5 rating from 355 ratings on the United States App Store.
- Received Germany's and joined the and startup programs.
- Placed second in the 2025 Advanced Electronics Challenge with the Belle Ring.
- Won both the jury and audience prizes at the 2025 Female StartAperitivo Central Germany competition and reached the Health-i Award's national top ten.
Team
Victoria Schoeffel
CEO and Co-Founder
- Earned a Bachelor of Medicine from the University of Cambridge.
- Completed a master's degree in philosophy of science at Columbia University as a Fulbright scholar.
Rafael Schaider
CTO and Co-Founder
- Became Lead Engineer at in 2022 after joining the company as a hardware engineer in 2020.
- Completed the University of Cambridge's program in 2022.
- Earned a Diplôme d'Ingénieur from École des Mines d'Alès.
Product
Belle combines a mobile cycle and symptom tracker with a structured therapy program and the Belle Ring. The app is available on iOS and Android. The ring sells for $299 and adds passive monitoring without requiring a separate ring subscription.
Built around prospective symptom tracking
Users record symptoms, mood, sleep, pain, and cycle information each day. Patterns emerge across successive cycles and can be exported for discussions with healthcare professionals.
An eight-week cognitive behavioral therapy program
The structured course covers stress management, thought patterns, and health behaviors. It was developed with clinical psychologists and forms the intervention evaluated in Belle's university studies.
Biometrics interpreted in cycle context
Eight sensors measure temperature, heart rate, heart rate variability, sleep, and movement. Belle interprets these signals against the wearer's hormonal rhythm to identify cycle-linked patterns and prepare for more difficult days.
Market Overview
Premenstrual dysphoric disorder can produce severe symptoms for several days during every menstrual cycle and continue throughout a woman's reproductive years. Diagnosis remains difficult because clinicians need prospective symptom records across at least two cycles, while patients in a 2026 Australian survey consulted an average of 5.1 healthcare professionals before receiving a diagnosis.
Menstrual health apps already form a large paid consumer category, led by platforms such as Flo. Belle targets a narrower clinical need by combining cycle records with structured support for severe symptoms. Germany provides an additional insurer-funded route, although reimbursement requires clinical evidence and formal approval beyond CE marking.
Estimated cumulative time spent with severe symptoms, based on 6.4 symptomatic days across approximately 459 menstrual cycles.
Average number consulted by 267 Australian patients while seeking a PMDD diagnosis.
's paid subscribers as of June 2024, alongside nearly 70 million monthly active users.
Estimated global market growth from 2025 to 2033, representing an 18.0% annual growth rate from 2026 onward.
Comparable Outcomes
Flo Health
Flo built a consumer subscription platform for cycle tracking, symptom monitoring, and personalized women's health content, reaching close to five million paid subscribers and nearly 70 million monthly active users. In 2024, invested more than $200 million in Flo's Series C, valuing the company at more than $1 billion.
Livongo Health
built a consumer app paired with connected devices, sold to employers and health plans, that coached people through diabetes and other long-term conditions day by day. Livongo proved that a daily consumer app can be paid for by an insurer rather than the user. completed the merger with Livongo on 30 October 2020 at a value of $18.5B.
Oura
built a consumer smart ring that tracks biometric signals such as sleep, heart rate, temperature, activity, and readiness. The product turned continuous personal health monitoring into a mainstream consumer category. Oura reached $1 billion in revenue in 2025 and was valued at $11 billion ahead of its expected IPO, showing large-scale demand for products that translate physiological data into personal health feedback.
Have a question about Belle Health?
Ask DealBio. We may research the answer or share selected questions with the company.
Sources
This profile was built from public company materials, ecosystem sources, market references, and professional profiles.